bioAffinity Technologies (BIAF) Projected to Release Earnings on Wednesday

bioAffinity Technologies (NASDAQ:BIAF) will likely be releasing its Q3 2026 results before the market opens on Wednesday, November 18th. Analysts expect the company to announce earnings of ($31.50) per share and revenue of $1.91 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 6, 2026 at 7:00 AM ET.

bioAffinity Technologies (NASDAQ:BIAF) last released its quarterly earnings data on Friday, November 6th. The company reported ($5.89) earnings per share for the quarter, beating the consensus estimate of ($31.50) by $25.61. bioAffinity Technologies had a negative net margin of 278.90% and a negative return on equity of 278.67%. The company had revenue of $1.07 million during the quarter, compared to analyst estimates of $1.91 million.

bioAffinity Technologies Stock Up 5.8%

bioAffinity Technologies stock opened at $2.39 on Wednesday. The company has a quick ratio of 1.41, a current ratio of 1.44 and a debt-to-equity ratio of 0.14. bioAffinity Technologies has a 12-month low of $2.25 and a 12-month high of $80.70. The firm’s fifty day moving average is $5.80 and its 200 day moving average is $18.51. The company has a market capitalization of $1.44 million, a PE ratio of -0.05 and a beta of -1.03.

Analysts Set New Price Targets

A number of research firms have commented on BIAF. Weiss Ratings restated a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Friday, October 16th. Wall Street Zen raised shares of bioAffinity Technologies from a “sell” rating to a “hold” rating in a research note on Monday, August 10th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

About bioAffinity Technologies

bioAffinity Technologies, Inc. is a biotechnology company focused on developing diagnostic and therapeutic products for cancer and other serious diseases. The company’s platform uses porphyrin-based compounds designed to selectively identify or target abnormal cells, with the goal of supporting earlier disease detection and more precise treatment. Its lead diagnostic product, CyPath Lung, is an investigational, noninvasive urine test intended to aid in the detection of lung cancer. The test uses an inhaled porphyrin compound that can bind to cancer cells in the lungs; the resulting material is collected in urine and analyzed using laboratory methods.